Literature DB >> 8892604

Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity.

N Fang1, D G Motto, S E Ross, G A Koretzky.   

Abstract

SLP-76 (SH2 domain leukocyte protein of 76 kDa) is a recently identified substrate of the TCR-stimulated protein tyrosine kinases that functions in the signal transduction cascade linking the TCR with IL-2 gene expression. In this report, we demonstrate that engagement of the TCR results in tyrosine phosphorylation of SLP-76 in its amino-terminal acidic region. Two tyrosines (Y113 and Y128) fall within an identical five amino-acid motif and are shown to be phosphorylated upon TCR ligation. Although mutation of either Y113 and Y128 has a minimal effect on SLP-76 function, mutation of both residues decreases significantly the ability of SLP-76 to promote T cell activation. A third tyrosine within the amino-terminal region (Y145) appears to be the most important for optimal SLP-76 function, as altering it alone to phenylalanine has a potent impact on SLP-76 augmentation of NFAT promoter activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892604

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Organization of complex situations in the immune system. Conference: signal processing through protein complexes.

Authors:  M Huber
Journal:  EMBO Rep       Date:  2000-10       Impact factor: 8.807

Review 2.  Recent developments in lymphocyte activation: linking kinases to downstream signaling events.

Authors:  J L Clements; G A Koretzky
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 3.  Regulation of hematopoietic cell development and activation by adapter proteins.

Authors:  Gary A Koretzky; Farhad Abtahian; Geo S Derimanov; Sally A Dmowski; Anastasia Guerriero; Martha S Jordan; Jonathan S Maltzman; Benjamin A Olenchock; Andrew L Singer; Jennifer N Wu; Xiao-Ping Zhong
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells.

Authors:  Meirav Sela; Yaron Bogin; Dvora Beach; Thomas Oellerich; Johanna Lehne; Jennifer E Smith-Garvin; Mariko Okumura; Elina Starosvetsky; Rachelle Kosoff; Evgeny Libman; Gary Koretzky; Taku Kambayashi; Henning Urlaub; Jürgen Wienands; Jonathan Chernoff; Deborah Yablonski
Journal:  EMBO J       Date:  2011-07-01       Impact factor: 11.598

5.  Differential T-cell antigen receptor signaling mediated by the Src family kinases Lck and Fyn.

Authors:  M F Denny; B Patai; D B Straus
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

6.  Structural requirements of SLP-76 in signaling via the high-affinity immunoglobulin E receptor (Fc epsilon RI) in mast cells.

Authors:  Alexander Kettner; Vadim Pivniouk; Lalit Kumar; Hervé Falet; Jeng-Shin Lee; Richard Mulligan; Raif S Geha
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Scaffold Protein SLP-76 Primes PLCγ1 for Activation by ITK-Mediated Phosphorylation.

Authors:  Sujan Devkota; Raji E Joseph; Lie Min; D Bruce Fulton; Amy H Andreotti
Journal:  J Mol Biol       Date:  2015-04-25       Impact factor: 5.469

8.  Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein.

Authors:  Xiaohong Wang; Ju-Pi Li; Li-Li Chiu; Joung-Liang Lan; Der-Yuan Chen; Jonathan Boomer; Tse-Hua Tan
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

9.  T-cell receptor early signalling complex activation in response to interferon-alpha receptor stimulation.

Authors:  Claire N Stevens; Ann-Marie Simeone; Susan John; Zamal Ahmed; Orso M Lucherini; C Tatiana Baldari; John E Ladbury
Journal:  Biochem J       Date:  2010-05-27       Impact factor: 3.857

10.  Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice.

Authors:  J L Clements; J R Lee; B Gross; B Yang; J D Olson; A Sandra; S P Watson; S R Lentz; G A Koretzky
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.